CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 79 enrolled
Drug / intervention
AngioSafe Peripheral CTO Crossing Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04663867
NCT04663867N/ACompleted
CompareCT.gov

Safety and Effectiveness Study of the AngioSafe Peripheral CTO Crossing System

AngioSafe, Inc.·interventional·Posted Dec 11, 2020·Updated Feb 12, 2026

In Brief

A clinical study evaluating AngioSafe Peripheral CTO Crossing System for Peripheral Artery Occlusion and Peripheral Arterial Disease. Completed, enrolled 79 participants across 18 sites.

Detailed Summary

The study is designed to evaluate the safety and efficacy of the AngioSafe Peripheral CTO Crossing System.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Artery Occlusion, Peripheral Arterial Disease
CountriesUnited States
CollaboratorsVeranex, Inc.

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 11, 2020
Enrollment StartFeb 3, 2021
Primary CompletionApr 25, 2023
Study CompletionJun 15, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.6 years ago

Interventions

AngioSafe Peripheral CTO Crossing Systemdevice

The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.